111 results about "Oa osteoarthritis" patented technology

The invention discloses a super-lubricating hydrogel microsphere, a preparation method and application in osteoarthritis treatment, and relates to the technical field of super-lubricating hydrogel interfaces. The super-lubricating hydrogel microsphere is of a core-shell structure and comprises an inner core and an outer shell; the inner core is a sodium alginate hydrogel microsphere, and the shell is a hydration layer. The sodium alginate hydrogel microspheres serve as an inner core and provide a stable structural basis, and the hydration layer serves as a shell and can keep moisture, so that friction is reduced in the movement process. The super-lubricity hydrogel microspheres provided by the invention have super lubricity, excellent biocompatibility and degradability, and can provide buffer for friction between articular cartilages, change sliding friction into rolling friction, relieve cartilage wear and delay the progress of osteoarthritis.

The present invention relates to a pharmaceutical composition with joint repair efficacy, which is composed of collagen, chitosan and a pharmaceutically acceptable carrier, wherein the weight ratio of collagen to chitosan in the composition is 11:1-1:11, the average molecular weight of collagen is 3kDa-500kDa, and the weight average molecular weight of chitosan is 10000-200000. The pharmaceutical composition of the present invention is used to treat and relieve pain caused by joint cavity stenosis and bone wear, effectively prevent and treat traumatic or degenerative osteoarthritis, and has the advantages of good water solubility, good biocompatibility, fast onset, good repair effect, good stability, good re-dissolution stability, long effective period, easy storage, etc.

The invention discloses an application of tiopronin wrapped by ROS (reactive oxygen species) response hydrogel in preparation of a medicine for treating osteoarthritis. The ROS response hydrogel is prepared from the following components: tiopronin; the compound group of lecithin and ketal thiol (TK) is TK-NH22, 2 '-(propane-2, 2-diyl bis (sulfanilamide diyl)) diethylamine (sulfanediyl), and the compound group of lecithin and ketal thiol (TK) is TK-NH22, 2'-(propane-2, 2-diyl bis (sulfanilamide diyl)); 12 wt% of methyl cellulose, Na2HPO4. 12H2O and xylitol; according to the hydrogel, controlled release of tiopronin is achieved through an ROS response group, mitochondrial autophagy is enhanced by up-regulating a Bnip3-Pink1-Parkin signal channel, oxidative stress is inhibited, and the progress of osteoarthritis is delayed; compared with the prior art, the invention has the advantages that: the invention discloses an osteoarthritis treatment medicine with the effects of resisting inflammation, relieving pain and inhibiting cartilage degeneration for the first time, and discloses a knee joint intracavity administration route of tiopronin for the first time. Particularly, the tiopronin targeted activation Bnip3-Pink1-Parkin signal channel provided by the invention has a remarkable effect in the aspect of inhibiting the progress of OA, which proves that the medicine has a strong effect on the treatment of osteoarthritis.

The invention is applicable to the technical field of medicine, and provides application of MgAl-LDH in preparation of a medicine for treating joint inflammation, LDH / RH-Gel for joint cavity injection is prepared by taking MgAl-LDH (magnesium aluminum hydrotalcite) as a carrier and carrying RH with anti-inflammatory and cartilage repair activity and combining with temperature-sensitive gel (Gel) by utilizing the advantages of joint cavity injection administration. The preparation is good in biological safety, the solubility of the RH is remarkably improved, and the residence time of the RH in an articular cavity is prolonged; the inflammatory response and cartilage loss are remarkably reduced, the disease progress is delayed, and the OA is effectively treated. The scheme is also suitable for delivery of joint inflammation treatment drugs such as non-steroidal anti-inflammatory drugs, hormone drugs, biological factors and monoclonal antibodies. And the MgAl-LDH can also form a composite carrier with other gels. The traditional Chinese medicine composition is expected to be used for treating arthritis diseases such as rheumatism, rheumatoid arthritis, osteoarthritis and synovitis.

Methods and compositions for treating centralized pain are disclosed. Methods and compositions for reducing pain or improving physical function are disclosed. In certain aspects, the subject has centralized pain and osteoarthritis of the knee and / or hip and the anti-NGF antibody is fasinumab.

The invention belongs to the technical field of medical treatment, and discloses an osteoarthritis rehabilitation auxiliary device and system, and the device comprises an intelligent vibration treatment module, a pressure sensor and biological feedback module, an intelligent control and APP remote management module, a pressure sensor, an accelerometer, and a myoelectricity sensor. The joint pain is relieved, vibration can stimulate sensory nerves, pain signal transmission is reduced, and the pain degree is reduced. Vibration promotes secretion of joint fluid, friction is reduced, and the range of motion is improved. Low-frequency vibration stimulates the activity of cartilage cells, and cartilage degeneration is slowed down. And a biological feedback system is intelligently regulated and controlled, so that the treatment accuracy is improved. Non-invasive treatment is achieved, and no side effect exists; gastrointestinal discomfort caused by drug treatment or high cost of long-term physical treatment is avoided. Remote monitoring is achieved, compliance is improved, a patient can be treated at home and does not need to see a doctor frequently, and medical cost is reduced.

There is provided a method of diagnosis comprising providing a sample previously isolated from a subject and analysing the sample for presence of a peptide comprising the amino acid sequence N- terminal-KSSTG (SEQ ID NO 1). The diagnosis may be for example diagnosis of a disease is selected from: osteoarthritis, early stage osteoarthritis, moderate osteoarthritis, osteoarthritis associated with risk for chip fractures of the joint or risk for avulsion fractures, severe osteoarthritis, microfractures of the joints, avulsion fractures and chip fractures of the joint.

The invention provides a pharmaceutical composition for bone joints as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition is prepared from the following components in parts by weight: 20 to 2000 parts of N-acetylglucosamine and 10 to 1000 parts of non-denatured type II collagen. In the compound composition of the N-acetylglucosamine and the non-denatured type II collagen, the two core components play a complementary role: the N-acetylglucosamine is focused on promoting synthesis of a cartilage matrix and provides a material basis for cartilage repair; the non-denatured type II collagen reduces damage of autoimmune response to cartilage through immunoregulation, the non-denatured type II collagen and the non-denatured type II collagen have a synergistic effect, the symptoms such as arthralgia and swelling can be relieved, the joint structure can be improved from the double angles of repairing and protecting, and particularly the treatment effect on patients with severe osteoarthritis is remarkably superior to that of a single-component preparation; and an innovative and efficient choice is provided for the treatment of osteoarticular diseases.

The invention proves that the isosakuranetin can inhibit the generation of osteoclasts and the functions of the osteoclasts in vitro, protect the bone microstructure of subchondral bones of an OA (osteoarthritis) mouse, relieve the degeneration of articular cartilage of the OA mouse, inhibit the generation of abnormal blood vessels in subchondral marrow cavities in the progress of the OA, and inhibit the osteoclasts in the osteoclasts. The invention proves that the isosakuranetin has a treatment effect on the osteoarthritis for the first time, and discloses an action mechanism of the isosakuranetin.

A novel PACE4 inhibitor and use thereof in anti-osteoarthritis. A novel PACE4 inhibitory peptide is designed and synthesized, which can effectively inhibit the expression of extracellular PACE4 without affecting normal cells, and is stable in joints and unstable in plasma, so that the PACE4 inhibitory peptide has excellent safety and can be effectively used in the prevention and treatment of OA.

The invention discloses a method for establishing a cat osteoarthritis pain model, which comprises the following steps of: performing experimental research on immunogen, drug concentration, immunization frequency, administration route, injection dosage and the like, and adopting collagen immunogen and 1% carrageenan immunogen as mixed immunogen; a cat is immunized by adopting a two-point injection mode of subcutaneous injection near a shoulder blade and plantar subcutaneous injection, the immunization procedure adopts twice immunization of 0 day and 7 days, a simple and efficient cat osteoarthritis pain model is successfully constructed, the model has obvious joint and claw swelling, a cat claw retraction threshold value is reduced, a TNF-a factor is obviously increased, and the model can be used for researching the pain of the cat osteoarthritis, the pain of the cat osteoarthritis and the pain of the cat osteoarthritis. The method can be used for researching the pathogenesis, pathological change, pain mechanism and OA treatment method of the cat osteoarthritis, and can also be used for evaluating the clinical effect of a novel analgesic drug for the cat osteoarthritis.

Compositions and methods for improving chondrogenesis, or treating osteoarthritis, or treating joint degradation or treating an osteochondral defect in a subject.

The present invention discloses the use of a benzenesulfonamide compound in the preparation of a medicament for preventing and / or treating osteoarthritis. This invention proposes for the first time the use of a benzenesulfonamide compound in a medicament for preventing and / or treating osteoarthritis. Experiments have shown that administration of a benzenesulfonamide compound can significantly improve joint swelling and wear in osteoarthritis mice; at the same time, the benzenesulfonamide compound can significantly reduce cartilage damage and inhibit the progression of joint fibrosis in osteoarthritis mice; in addition, the benzenesulfonamide compound significantly inhibits the expression of inflammation-related markers in the serum of osteoarthritis model mice. The above experiments demonstrate that benzenesulfonamide compounds can improve osteoarthritis and are of great significance for the future development of drugs and the prevention and treatment of such diseases.

The invention discloses a magnetocaloric therapeutic apparatus for osteoarthritis diseases, which comprises a magnetocaloric therapeutic apparatus main body and magnetocaloric massage balls, a motor box is fixedly mounted on the left side of the magnetocaloric therapeutic apparatus main body, a transmission shaft is mounted in the magnetocaloric therapeutic apparatus main body, and a hot compress table is mounted at the top end of the magnetocaloric therapeutic apparatus main body. A treatment seat is arranged at the top end of the magnetic thermal treatment device main body, a position adjusting block is arranged in the magnetic thermal treatment device main body, and a lifting adjusting frame is arranged on the surface of the magnetic thermal treatment device main body. According to the magnetocaloric therapeutic apparatus, the magnetocaloric massage balls emit heat to conduct hot compress on bone joints of a patient, meanwhile, the servo motor rotates to enable the hot compress table to horizontally move back and forth at the top end of the magnetocaloric therapeutic apparatus body, and in this way, the magnetocaloric massage balls can massage the bone joints of legs while conducting hot compress on the patient; the position of the treatment seat can be correspondingly adjusted according to the use requirements of a patient, and when the grip is held and lifted, an upward pulling force can be generated on the patient.

Disclosed herein are compositions comprising or consisting of Lactobacillus acidophilus and one or more prebiotics. Also disclosed herein are methods for treating osteoarthritis, inhibiting or preventing cartilage degeneration, and reducing or inhibiting pain-associated depression in subjects with joint pain with compositions comprising or consisting of Lactobacillus acidophilus and one or more prebiotics.

The invention discloses a parasitic loranthus exosome-like nano vesicle and application thereof in preparation of a medicine for treating temporomandibular joint osteoarthritis. The taxillus sutchuenensis exosome-like nano-vesicles are prepared by combining a differential ultracentrifugation method with an ultrafiltration method. Researches show that the taxillus sutchuenensis exosome-like nano-vesicles can treat temporomandibular joint osteoarthritis through the following aspects: 1) an anti-inflammatory function: effectively reducing expression of inflammatory factors; 2) a cartilage degeneration inhibition function: blocking a cartilage matrix degradation pathway, and slowing down cartilage tissue damage; the taxillus sutchuenensis exosome-like nano-vesicles have the advantages that the taxillus sutchuenensis exosome-like nano-vesicles have obvious protection and repair effects on relieving temporal-mandibular joint osteoarthritis related bone and cartilage damage, and accordingly the taxillus sutchuenensis exosome-like nano-vesicles have good application prospects.

The invention discloses a novel PACE4 inhibitor and application of the novel PACE4 inhibitor in resisting osteoarthritis. The novel PACE4 inhibitory peptide designed and synthesized by the invention can effectively inhibit expression of extracellular PACE4 without influencing normal cells, and is stable in joints and unstable in plasma, so that the novel PACE4 inhibitory peptide has excellent safety and can be effectively used for preventing and treating OA.

The present invention relates to a method of screening for osteoarthritis (OA) and rheumatoid arthritis (RA) in a subject suffering from arthritis or suspected of suffering from arthritis and a method of discriminating between OA and rheumatoid arthritis RA comprising determining the level of one or more glycosaminoglycan (GAG) properties according to the invention in a sample of bodily fluid. The invention also provides methods for monitoring OA or RA progression in a subject suffering from arthritis.

The present invention provides compositions and methods for treating joint disorders characterized by inflammatory components. In certain aspects, the compositions and methods are useful for preventing the progression of and treating osteoarthritis and other arthritis in mammalian joints.

The invention discloses an application of mPGES-2 as a target spot in developing, screening or preparing a medicine for preventing and / or treating osteoarthritis. The invention proposes that mPGES-2 is a drug target of osteoarthritis for the first time. Experiments show that mPGES-2 knockout can significantly relieve joint swelling, protect cartilage wear, improve bone metabolism abnormality and inhibit release of inflammatory factors; meanwhile, the mPGES-2 has a remarkable effect on improving osteoarthritis, can be used as a target spot for treating osteoarthritis, and is of great significance to development, prevention and treatment of drugs for the diseases in the future.

The present invention demonstrates that isosakurabin can inhibit the formation and function of osteoclasts in vitro, protect the bone microstructure of the subchondral bone in mice with osteoarthritis (OA), reduce articular cartilage degeneration in OA mice, inhibit the formation of abnormal blood vessels in the subchondral bone marrow cavity during OA progression, and alleviate joint pain induced by abnormal osteoclast activation in OA mice. This invention demonstrates for the first time that isosakurabin has a therapeutic effect on osteoarthritis and reveals its mechanism of action.

The invention discloses application of chlorella in preparation of a medicine for treating osteoarthritis, in-vivo experiments and in-vitro experiments prove that chlorella can maintain a chondrocyte metabolism steady state, inhibit expression of chondrocyte extracellular matrix catabolism-related genes and proteins, and inhibit osteoarthritis. The expression of genes and proteins related to chondrocyte extracellular matrix anabolism is promoted, and by injecting a chlorella solution into a knee joint cavity, the effects of relieving and improving OA pain are achieved; furthermore, polydopamine is used for modifying the chlorella to obtain the polydopamine-coated chlorella Ch (at) P with a photothermal effect, and the Ch (at) P not only maintains the biological activity of the chlorella, but also has the effect of delaying cartilage degeneration and OA process due to the photothermal effect under near infrared (NIR) irradiation.

The application discloses a joint cavity filling preparation of precisely proportioned carboxymethyl chitosan and sodium glycerophosphate and a preparation method and application thereof, and the effective component of the filling preparation is carboxymethyl chitosan with a concentration of 25 mg / mL and sodium glycerophosphate with a concentration of 15 mg / mL, and the balance is a sterile isotonic physiological buffer aqueous solution. The application forms component synergy by relying on the lubrication and long-acting stability characteristics of carboxymethyl chitosan and combining the structure reinforcement, ion regulation and cartilage repair promoting characteristics of sodium glycerophosphate, and effectively solves the defects of short in-vivo retention time, poor mechanical stability, lack of biological repair activity and easy dilution and collapse of the traditional joint filling material in the joint cavity fluid. The application overcomes the problem that a high-concentration viscous solution cannot be filtered and sterilized, can effectively buffer the joint mechanical load, optimize the joint microenvironment and promote the repair of degenerative cartilage, is suitable for clinical scenes such as mild and moderate osteoarthritis, sports joint injury and postoperative joint function repair, and has good clinical application value and industrialization prospect.

The invention discloses an RIP3-mediated osteoarthritis animal model as well as a construction method and application thereof. The construction method comprises the following steps: delivering an effective dose of a genetic tool (such as an adenovirus vector) capable of expressing RIP3 protein into a knee joint subchondral bone area of an experimental animal, and realizing continuous overexpression of RIP3 through regular operation, so as to induce pathological characteristics highly similar to human osteoarthritis. The model stably shows typical OA phenotypes such as limb pain sensitization, subchondral bone loss and bone microstructure degeneration, osteoclast number increase and overlying cartilage degeneration. The invention reveals that the natural process of occurrence and development of the osteoarthritis can be directly simulated through specific overexpression of the RIP3 in the subchondral bone for the first time, and a brand-new and valuable tool is provided for researching the pathogenesis of the osteoarthritis and screening and evaluating medicines and therapies for treating the osteoarthritis.

The present invention relates to the field of nutraceuticals, specifically to a synergistic bioactive composition designed to improve joint health. This composition comprises Palmitoylethanolamide (PEA) and Cucumis sativus, aimed at reducing joint pain and protecting cartilage. It addresses the complex pain components of osteoarthritis, including both nociceptive pain, which stems from ongoing joint inflammation and tissue damage, and neuropathic pain, which indicates nerve damage. This nutraceutical composition provides a novel solution for mitigating the debilitating effects of osteoarthritis through oral administration, utilizing pharmaceutically acceptable excipients to ensure efficacy and safety.

The invention discloses an application of a cathepsin D inhibitor in preparation of a medicine for preventing or treating osteoarthritis, and an application of the cathepsin D inhibitor in preparation of a medicine for inhibiting degradation of type II collagen and / or articular cartilage. The invention relates to an application of a cathepsin D inhibitor in preparation of drugs for inhibiting expression of cathepsin D in bone joints. In the application, the cathepsin D can effectively relieve tissue lesions of osteoarthritis.

By using the helical axis in the knee joint movement of subjects during walking, we perform gait analysis that can be used to detect early-stage osteoarthritis of the knee. [Solution] A gait analysis method comprising the steps of: calculating the helical axis of the knee joint based on motion data of the subject's lower limbs during walking; extracting the flexion phase and extension phase during the stance phase of the subject's gait cycle; and obtaining an evaluation value to assess the condition of the knee by quantifying the variability of the helical axis group in one or both of the flexion phase and the extension phase.

The invention provides application of querceric acid in preparation of a medicine for improving osteoarthritis, and belongs to the technical field of medicines. The invention provides a novel application of the quercetin. The research finds that the quercetin can obviously reduce the joint diameter of a mouse with osteoarthritis, improve the joint swelling degree of the mouse with osteoarthritis, improve the joint movement function limitation degree of the mouse with osteoarthritis and effectively reduce the sensitivity of the mouse with osteoarthritis to nociceptive stimulation; the quercetin can also effectively improve liver and spleen pathological changes induced by MIA. The invention relates to an application of quercetin in preparation of a medicine for improving osteoarthritis.

The present invention provides compositions and methods for treating joint disorders that are characterized by an inflammatory component. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint.

The osteoarthritis self-adaptive load-bearing damping brace comprises a hook-and-loop fastener, a clamping and fixing unit capable of reducing the bending pressure of a knee joint is arranged on the back face of the hook-and-loop fastener, and a movable supporting unit for tightly attaching and protecting the knee joint is arranged on the side face of the clamping and fixing unit. The clamping and fixing unit comprises a movable middle shaft which is arranged on the side face of the hook-and-loop fastener and used for fixing different leg types; the two shells are placed at the bottoms of the thighs and the tops of the shanks of a user respectively, it is ensured that the two shells can be driven to be folded in the direction of the inclined supporting blocks when the legs are bent, at the moment, movable middle shafts are installed on the side faces of the shells, and it is ensured that push plates are tightly attached to the thigh peak of a patient; the binding band is installed in the side face of the shell, the movable middle shaft is bound to the legs of a user through cooperation of the binding band, the fixing buckle and the hook-and-loop fastener, at the moment, the movable clamping plate tightly wraps the legs of the user under the thrust of the movable middle shaft and the guide of the inclined face of the base plate, and the stability of the device in daily movement is guaranteed.